| Literature DB >> 30303355 |
Mohammed A Aljama1, M Hasib Sidiqi1, David Dingli2.
Abstract
Despite significant progress in our understanding and the development of novel therapies, most patients with multiple myeloma will experience relapse of their disease. Therapy of relapsed myeloma has improved due to the availability of novel agents that are highly active against the disease. However, the selection of therapy can be challenging due to the emergence of toxicities, comorbidities and frailty. In the following we discuss our approach to the treatment of the patient with relapsed myeloma.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30303355 DOI: 10.23736/S0031-0808.18.03542-5
Source DB: PubMed Journal: Panminerva Med ISSN: 0031-0808 Impact factor: 5.197